Inventiva

Equities

IVA

FR0013233012

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 16:35:26 20/06/2025 BST			5-day change	1st Jan Change
2.780 ^EUR	-2.46%		-4.96%	+27.52%

06-10	Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors	RE
06-10	Inventiva Announces the Appointment of Renée Aguiar-Lucander to Its Board of Directors	CI

Inventiva: UBS Group exceeds 5% of share capital

Published on 11/07/2024 at 09:51, updated on 11/07/2024 at 09:54

On July 4, UBS Group declared to the AMF that, through its subsidiaries, it had exceeded the threshold of 5% of Inventiva's capital and held, directly and indirectly, 5.16% of the capital and 4.14% of the voting rights of the biopharmaceutical company.

This threshold crossing is the result of an off-market acquisition of Inventiva shares, as a result of which the trading exemption no longer applies to the declarant", explains the Swiss financial institution.

Copyright (c) 2024 CercleFinance.com. All rights reserved.

Go to the original article.
Legal disclaimer

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	UBS GROUP AG	24.92CHF	+0.65%	-4.52%	93.55B
	INVENTIVA	2.780EUR	-2.46%	-4.96%	446M

Latest news about Inventiva

Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors	06-10	RE
Inventiva Announces the Appointment of Renée Aguiar-Lucander to Its Board of Directors	06-10	CI
Inventiva SA Reports No Revenues For Q1 2025	05-23	RE
Inventiva SA - Maximum Repurchase Price Set At 40 Euros Per Share	05-22	RE
A month of zero gains on the stock market in April?	05-05
Inventiva Secures Second Tranche of EUR348 Million Financing	05-05	MT
Inventiva Secures Second Tranche Under Structured Financing Of Max. EUR 348 Mln	05-05	RE
Inventiva Announces the Publication in Clinical Gastroenterology and Hepatology of Its Analysis of New Biomarker Signatures Predictive of Histological Response in Patients with Mash Treated with Lanifibranor	04-24	CI
Inventiva S.A. Auditor Raises 'Going Concern' Doubt	04-14	CI
Inventiva Completes Enrollment in Phase 3 Study of Liver Treatment	04-01	MT
Inventiva Announces Completion of Patient Enrollment in Its NATiV3 Phase 3 Clinical Trial	04-01	CI
Inventiva Says Topline Results From NATiV3 Expected In Second Half Of 2026	04-01	RE
Inventiva S.A., 2024 Earnings Call, Mar 27, 2025	03-27
Inventiva Reports Its 2024 Full Year Results And Provides A Business Update	03-26	RE
Inventiva S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	03-26	CI
Inventiva: launch of a clinical study in Japan	02-21	CF
Inventiva S.A. and Hepalys Pharma, Inc. Announce the Initiation of the Clinical Development Program of Lanifibranor in Japan	02-20	CI
Inventiva SA - To Focus On Lanifibranor, Stop Preclinical Research, Reduce Workforce By 50%	02-10	RE
Inventiva S.A. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-15-2025 03:45 PM	01-15
Inventiva Splits CEO, Board Chairman Roles	12-16	MT
Inventiva Completes First Tranche of EUR348 Million Financing	12-16	MT
Inventiva to Present Data from the Final Analysis of the Phase 2 Study Evaluating the Combination of Lanifibranor with Empagliflozin in Patients with Mash and T2d At the Aasld the Liver Meeting® Late-Breaker Session	11-15	CI
Inventiva Announces the Positive Recommendation of the Fifth DMC of the Nativ3 Phase 3 Clinical Trial with Lanifibranor in Patients with Mash	30/10/24	CI
Top Premarket Decliners	16/10/24	MT
Top Premarket Gainers	14/10/24	MT

Chart Inventiva

Duration

Period

IVA: Dynamic Chart

Company Profile

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly owned research and development facility.

Employees

116

Sector

Biotechnology & Medical Research

Calendar

06-23 - UBS Spring Biotech Conference

More about the company